Bolt Biotherapeutics Inc

Bolt Biotherapeutics Inc

BOLT - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$11.71M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Bolt Biotherapeutics IncBolt Biotherapeutics Inc-0.4--304%6.12.6

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$11.71 Million
Enterprise Value$19.89 Million
Earnings per Share$-17.85
Beta1.01
Outstanding Shares1,966,084

Return

Return on Equity-303.87%ROE
Return on Assets-73.10%
Return on Invested Capital-98.36%

Valuation & Multiples

P/E Ratio-0.42P/E Ratio
PEG1.1PEG
Price to Sales6.08Price to Sales
Price to Book Ratio1.52Price to Book Ratio
Enterprise Value to Revenue7.86
Enterprise Value to EBIT-0.74
Enterprise Value to Net Income-1
Total Debt to Enterprise1.1
Debt to Equity2.56Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS
-$2.25
Est. -$3.68
Revenue
$450,000
Est. $450,000

Next Earnings Call

Expected Date
March 11, 2027
EPS Estimate
-$2.01
Consensus analyst estimate
Revenue Estimate
$450,000
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %16.66%▼ 18.64%
Total Invested$1.03M▼ 55.28%
Investors Holding14▼ 10.00%

About Bolt Biotherapeutics Inc

65 employees

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjug...

Bolt Biotherapeutics Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in Bolt Biotherapeutics. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 2 open-market insider purchases and 9 open-market insider sales for Bolt Biotherapeutics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.